Tango Therapeutics, Inc. (TNGX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-01-08

Key Insights

  • Tango Therapeutics reported $343 million in cash, cash equivalents and marketable securities as of December 31, 2025, indicating a strong financial position.
  • The company announced the resignation of Barbara Weber, M.D. as President and CEO, and the appointment of Malte Peters, M.D. as the new President and CEO, effective January 8, 2026.
  • Tango Therapeutics granted Malte Peters, the new CEO, a compensation package including a base salary of $720,000, a target cash bonus of 60%, and equity awards of stock options and restricted stock units.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Tango Therapeutics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.